Zhi Tong Cai Jing·2025-12-24 09:17Group 1 - Green Leaf Pharmaceutical has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] - The three products include Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all aimed at treating schizophrenia [1][2] - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical as part of the agreement, which lasts for ten years [1] Group 2 - Schizophrenia is a chronic, high-recurrence, and highly disabling disease, with approximately 8 million patients in China [2] - Long-acting injectable antipsychotics significantly improve patient compliance compared to oral formulations, making them an important treatment strategy for preventing relapse [2] - The products are developed based on Green Leaf's long-acting and sustained-release technology platform, with Riketu being the first domestically developed second-generation long-acting injectable antipsychotic in China [2] Group 3 - The board believes that the three long-acting injectables form a differentiated product portfolio that addresses the treatment needs of schizophrenia patients at all stages of the disease [3] - CNS (Central Nervous System) is a core strategic area for the company, which aims to accelerate the realization of product pipeline value through strategic partnerships [3] - The collaboration with Enhua will enhance the coverage of these products in primary healthcare centers, helping more patients receive standardized treatment and reduce the burden of the disease [3]